3-((叔丁氧基羰基)氨基)-2,2-二甲基丙酸 | 180181-02-6

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-((叔丁氧基羰基)氨基)-2,2-二甲基丙酸
• 中文别名: 2,2-二甲基-3-(Boc-氨基)丙酸；2,2-二甲基-3-(BOC-氨基)丙酸
• 英文名称: 3-(tert-Butoxycarbonyl)amino-2,2-dimethylpropanoic Acid
• 英文别名: 3-((tert-Butoxycarbonyl)amino)-2,2-dimethylpropanoic acid；2,2-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 180181-02-6
• 化学式: C₁₀H₁₉NO₄
• mdl: MFCD09952625
• 分子量: 217.265
• InChiKey: LSZXQEWVQORQBO-UHFFFAOYSA-N

物化性质

• 沸点：
  346.5±25.0 °C(Predicted)
• 密度：
  1.082±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Boc-amino-2,2-dimethyl-propionic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Boc-amino-2,2-dimethyl-propionic acid
CAS number: 180181-02-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H19NO4
Molecular weight: 217.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-((叔丁氧基羰基)氨基)-2,2-二甲基丙酸 在 palladium on activated charcoal 4-二甲氨基吡啶 、 五氟苯基二苯基磷酸酯 、 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 46.5h， 生成 cryptophycin 52
  参考文献：
  名称：

  对映体合成有效的抗有丝分裂抗肿瘤药（+）-隐霉素52（LY355703）。

  摘要：

  描述了隐藻霉素52（2）的高度对映选择性和聚合反应，这是一种非常有效的细胞毒剂。隐藻霉素家族的一种合成变体-隐藻霉素52，目前正在临床试验中。合成是收敛的，涉及三个片段的组装，苯基己烯醛3，d-酪氨酸膦酸酯4和受保护的β-氨基酸衍生物5。片段3的合成涉及C-3和C3的两个立体发生中心的有效和立体控制的构建。通过酰基氧碳鎓离子中间体裂解取代的四氢呋喃环而得到C-4。这两个立体生成中心均来自光学活性的4-苯基丁内酯，其是通过Corey-Bakshi-Shibata还原对映选择性合成的。

  DOI：

  10.1021/jo035077v
• 作为产物：
  描述：

  3-氯-2,2-二甲基丙酸 在 sodium azide 、 palladium 10% on activated carbon 、 氢气 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 叔丁醇 为溶剂， 反应 37.0h， 生成 3-((叔丁氧基羰基)氨基)-2,2-二甲基丙酸
  参考文献：
  名称：

  NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

  摘要：

  本发明涉及一种新颖的化合物或其药物可接受的盐，该化合物抑制11β-HSD1酶活性，其制备方法，以及包含该化合物作为活性成分的药物组合物。由于本发明的化合物选择性地抑制11β-HSD1（11β-羟基类固醇脱氢酶1型）的活性，因此本发明的化合物可以有效地用作治疗由11β-HSD1过度激活引起的疾病的治疗剂，例如非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由糖皮质激素过度活动介导的疾病或状况。

  公开号：

  US20150210635A1

文献信息

• Cryptophycin compounds
  申请人：Eli Lilly and Company

  公开号：US06680311B1

  公开（公告）日：2004-01-20

  The present invention provides cryptophycin compounds of Formula I that are useful in the treatment of neoplasms.

  本发明提供了一种在肿瘤治疗中有用的Formula I的cryptophycin化合物。
• [EN] GLP-1 RECEPTOR MODULATORS<br/>[FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR DU GLP-1
  申请人：CELGENE INTERNAT II SARL

  公开号：WO2016094729A1

  公开（公告）日：2016-06-16

  Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "^^^^" represents either or both the R and S form of the compound) (I) where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

  提供了一些化合物，这些化合物可以调节胰高血糖素样肽1（GLP-1）受体，以及它们的合成方法，以及它们的治疗和/或预防使用方法。这类化合物可以单独作为GLP-1受体的调节剂或增强剂，或者与肠促胰岛素肽（如GLP-1(7-36)和GLP-1(9-36)）一起使用，或者与基于肽的治疗方法（如艾塞那肽和利拉鲁肽）一起使用，并具有以下一般结构（其中"^^^^"代表化合物的R和S形式中的一个或两个）(I) 其中A、B、C、Y1、Y2、Z、R1、R2、R3、R4、R5、W1、n、p和q的定义如下。
• [EN] NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE<br/>[FR] NOUVEAUX COMPOSÉS ET CONJUGUÉS DE CRYPTOPHYCINE, LEUR PRÉPARATION ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI SA

  公开号：WO2017076998A1

  公开（公告）日：2017-05-11

  The present invention relates to cryptophycin compounds of formula (I). The invention also relates to cryptophycin payloads, to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The invention also relates to the process for preparing these conjugates.

  本发明涉及公式（I）的隐藻素化合物。该发明还涉及隐藻素有效载荷、隐藻素偶联物、含有它们的组合物及其治疗用途，尤其是作为抗癌剂。该发明还涉及制备这些偶联物的过程。
• Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase
  作者：Philip A. Harris、Nicolas Faucher、Nicolas George、Patrick M. Eidam、Bryan W. King、Gemma V. White、Niall A. Anderson、Deepak Bandyopadhyay、Allison M. Beal、Veronique Beneton、Scott B. Berger、Nino Campobasso、Sebastien Campos、Carol A. Capriotti、Julie A. Cox、Alain Daugan、Frederic Donche、Marie-Hélène Fouchet、Joshua N. Finger、Brad Geddes、Peter J. Gough、Pascal Grondin、Bonnie L. Hoffman、Sandra J. Hoffman、Susan E. Hutchinson、Jae U. Jeong、Emilie Jigorel、Pauline Lamoureux、Lara K. Leister、John D. Lich、Mukesh K. Mahajan、Jamel Meslamani、Julie E. Mosley、Rakesh Nagilla、Pamela M. Nassau、Sze-Ling Ng、Michael T. Ouellette、Kishore K. Pasikanti、Florent Potvain、Michael A. Reilly、Elizabeth J. Rivera、Stéphane Sautet、Michelle C. Schaeffer、Clark A. Sehon、Helen Sun、James H. Thorpe、Rachel D. Totoritis、Paris Ward、Natalie Wellaway、David D. Wisnoski、James M. Woolven、John Bertin、Robert W. Marquis

  DOI：10.1021/acs.jmedchem.9b00318

  日期：2019.5.23

  RIP1 kinase inhibitors starting from a high-throughput screen and the lead-optimization of this series from a lead with minimal rat oral exposure to the identification of dihydropyrazole 77 with good pharmacokinetic profiles in multiple species. Additionally, we identified a potent murine RIP1 kinase inhibitor 76 as a valuable in vivo tool molecule suitable for evaluating the role of RIP1 kinase in chronic

  RIP1激酶调节坏死病和炎症，并可能在促成多种人类疾病（包括炎症和神经疾病）中发挥重要作用。目前，RIP1激酶抑制剂已进入早期临床试验，以评估炎性疾病（如牛皮癣，类风湿性关节炎和溃疡性结肠炎）以及神经系统疾病（如肌萎缩性侧索硬化症和阿尔茨海默氏病）。在本文中，我们从高通量筛选开始，研究了有效和高度选择性的二氢吡唑（DHP）RIP1激酶抑制剂的设计，并从具有最小大鼠口服暴露量的铅中对该系列的铅进行了优化，以鉴定二氢吡唑77在多个物种中具有良好的药代动力学特征。此外，我们确定了一种强效的鼠RIP1激酶抑制剂76作为一种有价值的体内工具分子，适用于评估RIP1激酶在慢性疾病模型中的作用。DHP 76在多发性硬化症和人类视网膜色素变性的小鼠模型中均显示出功效。
• A Convergent Approach to Cryptophycin 52 Analogues:  Synthesis and Biological Evaluation of a Novel Series of Fragment A Epoxides and Chlorohydrins
  作者：Rima S. Al-awar、James E. Ray、Richard M. Schultz、Sherri L. Andis、Joseph H. Kennedy、Richard E. Moore、Jian Liang、Trimurtulu Golakoti、Gottumukkala V. Subbaraju、Thomas H. Corbett

  DOI：10.1021/jm0203884

  日期：2003.7.1

  intermediate aldehyde prepared from Cryptophycin 53. Substitution on the phenyl ring of fragment A was well tolerated, and several of these analogues were equally or more potent than Cryptophycin 52 when evaluated in vitro in the CCRF-CEM leukemia cell line and in vivo against a murine pancreatic adenocarcinoma.

  隐藻霉素52是隐藻霉素1的合成衍生物，隐藻霉素1是一种从蓝细菌中分离出来的有效的抗微管剂。为了提高分子的效力和水溶性，围绕片段A的苯环展开了结构-活性关系研究（SAR）。使用多种三苯基phosph盐和四氢呋喃盐之间的Wittig烯化反应来获得这些隐藻霉素52类似物。由隐藻霉素53制备的关键中间体醛。在片段A的苯环上的取代具有良好的耐受性，当在CCRF-CEM白血病细胞系中进行体外评估并在体内针对甲氧西林鼠胰腺腺癌。